Mylan/3M launch new asthma inhaler; Another abuse-deterrent opioid being developed;

> Mylan ($MYL) announced the launch of the first bioequivalent alternative to GlaxoSmithKline's ($GSK) Seretide Evohaler in the United Kingdom, dubbed Sirdupla. The pressurized metered-dose inhaler to treat asthma will be manufactured by 3M Drug Delivery Systems. More

> Egalet said its investigational opioid passed tests of abuse deterrence. It demonstrated high resistance to crushing and grinding with 11 household tools, and heating the tablet did not alter its resistance to physical manipulation attempts, the company says. More